Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma

Overview

Journal Transl Oncol

Specialty Oncology

Date 2018 Feb 24

PMID 29475139

Citations 15

Authors

Md Sazzad Hassan

Niranjan Awasthi

Jun Li

Fiona Williams

Margaret A Schwarz

Roderich E Schwarz

Urs von Holzen

Affiliations

Soon will be listed here.

Abstract

Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20%. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is largely ineffective. Therefore, new therapeutic approaches are urgently needed. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel albumin-stabilized, cremophor-free and water soluble nanoparticle formulation of paclitaxel, and the potential role of nab-paclitaxel has not been tested yet in experimental EAC. Here we tested the antiproliferative and antitumor efficacy with survival advantage of nab-paclitaxel as monotherapy and in combinations in in-vitro, and in murine subcutaneous xenograft and peritoneal metastatic survival models of human EAC. Nab-paclitaxel significantly inhibited in-vitro cell proliferation with higher in-vivo antitumour efficacy and survival benefit compared to paclitaxel or carboplatin treatments both in mono- and combination therapies. Nab-paclitaxel treatment increased expression of mitotic-spindle associated phospho-stathmin, decreased expression of proliferative markers and enhanced apoptosis. This study demonstrates that nab-paclitaxel had stronger antiproliferative and antitumor activity in experimental EAC than the current standard chemotherapeutic agents which supports the rationale for its clinical use in EAC.

Citing Articles

Inhibition of Insulin-like Growth Factor 1 Receptor/Insulin Receptor Signaling by Small-Molecule Inhibitor BMS-754807 Leads to Improved Survival in Experimental Esophageal Adenocarcinoma.

Hassan M, Johnson C, Ponna S, Scofield D, Awasthi N, von Holzen U Cancers (Basel). 2024; 16(18).

PMID: 39335147 PMC: 11430189. DOI: 10.3390/cancers16183175.

Nanodrugs systems for therapy and diagnosis of esophageal cancer.

Zhang L, Li X, Yue G, Guo L, Hu Y, Cui Q Front Bioeng Biotechnol. 2023; 11:1233476.

PMID: 37520291 PMC: 10373894. DOI: 10.3389/fbioe.2023.1233476.

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers-Improvements in Clinical Efficacy and Safety.

Hassan M, Awasthi N, Ponna S, von Holzen U Biomedicines. 2023; 11(7).

PMID: 37509639 PMC: 10377238. DOI: 10.3390/biomedicines11072000.

Subcellular Organelle-Targeted Nanostructured Lipid Carriers for the Treatment of Metastatic Breast Cancer.

Dang W, Xing B, Jia X, Zhang Y, Jia B, Yu C Int J Nanomedicine. 2023; 18:3047-3068.

PMID: 37312934 PMC: 10259594. DOI: 10.2147/IJN.S413680.

Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy.

Zhang J, Li L, Yin J, Zhang X, Zheng Y, Feng R BMC Pharmacol Toxicol. 2023; 24(1):13.

PMID: 36859304 PMC: 9979565. DOI: 10.1186/s40360-023-00653-2.

References

Montana M, Ducros C, Verhaeghe P, Terme T, Vanelle P, Rathelot P . Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. J Chemother. 2011; 23(2):59-66. DOI: 10.1179/joc.2011.23.2.59. View

Bollschweiler E, Holscher A, Schmidt M, Warnecke-Eberz U . Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment. Chin J Cancer Res. 2015; 27(3):221-30. PMC: 4490195. DOI: 10.3978/j.issn.1000-9604.2015.04.04. View

Gros S, Kurschat N, Dohrmann T, Reichelt U, Dancau A, Peldschus K . Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma. Mol Cancer Ther. 2010; 9(7):2037-45. DOI: 10.1158/1535-7163.MCT-10-0209. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

Risinger A, Giles F, Mooberry S . Microtubule dynamics as a target in oncology. Cancer Treat Rev. 2009; 35(3):255-61. PMC: 2778221. DOI: 10.1016/j.ctrv.2008.11.001. View

Rowinsky E, Cazenave L, Donehower R . Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990; 82(15):1247-59. DOI: 10.1093/jnci/82.15.1247. View

Kordes S, Cats A, Meijer S, van Laarhoven H . Targeted therapy for advanced esophagogastric adenocarcinoma. Crit Rev Oncol Hematol. 2013; 90(1):68-76. DOI: 10.1016/j.critrevonc.2013.10.004. View

Zhang C, Awasthi N, Schwarz M, Hinz S, Schwarz R . Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. PLoS One. 2013; 8(2):e58037. PMC: 3584019. DOI: 10.1371/journal.pone.0058037. View

Devesa S, Blot W, Fraumeni Jr J . Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998; 83(10):2049-53. View

10.

Balasubramani M, Nakao C, Uechi G, Cardamone J, Kamath K, Leslie K . Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis. Mutat Res. 2010; 722(2):154-64. PMC: 3017223. DOI: 10.1016/j.mrgentox.2010.08.019. View

11.

Mistry S, Bank A, Atweh G . Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure. Mol Cancer Res. 2007; 5(8):773-82. DOI: 10.1158/1541-7786.MCR-06-0290. View

12.

Zamai M, vandeVen M, Farao M, Gratton E, Ghiglieri A, Castelli M . Camptothecin poly[n-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy. Mol Cancer Ther. 2003; 2(1):29-40. View

13.

Kresty L, Weh K, Zeyzus-Johns B, Perez L, Howell A . Cranberry proanthocyanidins inhibit esophageal adenocarcinoma in vitro and in vivo through pleiotropic cell death induction and PI3K/AKT/mTOR inactivation. Oncotarget. 2015; 6(32):33438-55. PMC: 4741777. DOI: 10.18632/oncotarget.5586. View

14.

Olive K, Jacobetz M, Davidson C, Gopinathan A, McIntyre D, Honess D . Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324(5933):1457-61. PMC: 2998180. DOI: 10.1126/science.1171362. View

15.

Hsieh S, Huang S, Yu M, Yeh T, Chen T, Lin Y . Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog. 2010; 49(5):476-87. DOI: 10.1002/mc.20627. View

16.

Domper Arnal M, Ferrandez Arenas A, Lanas Arbeloa A . Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015; 21(26):7933-43. PMC: 4499337. DOI: 10.3748/wjg.v21.i26.7933. View

17.

Drenckhan A, Kurschat N, Dohrmann T, Raabe N, Koenig A, Reichelt U . Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer. J Surg Res. 2012; 182(2):250-6. DOI: 10.1016/j.jss.2012.09.035. View

18.

Stanton R, Gernert K, Nettles J, Aneja R . Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev. 2011; 31(3):443-81. PMC: 3155728. DOI: 10.1002/med.20242. View

19.

Awasthi N, Zhang C, Ruan W, Schwarz M, Schwarz R . Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. PLoS One. 2012; 7(6):e38477. PMC: 3377661. DOI: 10.1371/journal.pone.0038477. View

20.

Di Paolo G, Antonsson B, Kassel D, Riederer B, Grenningloh G . Phosphorylation regulates the microtubule-destabilizing activity of stathmin and its interaction with tubulin. FEBS Lett. 1997; 416(2):149-52. DOI: 10.1016/s0014-5793(97)01188-5. View